Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan
plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis
International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals,
and Quidel Corporation. Market players are investing in research to development of novel
therapies to treat viral conjunctivitis.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1281
NiCox S.A. in March 2017, received the FDA approval for its ZERVIATE1 (cetirizine ophthalmic
solution 0.24%) as New Drug Application (NDA), which is the first antihistaminic topical ocular
formulation for the treatment of itching due to allergic conjunctivitis. Company is looking to
commercialize the product in the U.S. through partnership. In 2015, Shire plc announced
acquisition of Foresight Biotherapeutics for US$ 300 million. Foresight Biotherapeutics has
experimental eye drop FST-100 in its pipeline, which is a combination of 0.6% povidone iodine
and 0.1% dexamethasone to treat both viral and bacterial conjunctivitis. This acquisition would
add growth to Shire plc’s ophthalmic portfolio.
Viral Conjunctivitis Drugs Market Taxonomy:
On the basis of drug class:
• Artificial tears
• Decongestants
• Anti-histaminic
• NSAIDS
• Anti-Viral drugs
On the basis of the distribution channel:
• Hospital Pharmacy
• Retail Pharmacy
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.